Viewray (VRAY) Earns Buy Rating from Analysts at B. Riley
Investment analysts at B. Riley assumed coverage on shares of Viewray (NASDAQ:VRAY) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $13.50 price target on the stock. B. Riley’s price target suggests a potential upside of 71.32% from the stock’s previous close.
Other equities analysts also recently issued research reports about the company. Northland Securities reissued a “buy” rating and set a $10.00 price target on shares of Viewray in a research report on Friday, November 17th. Mizuho reissued a “buy” rating and set a $12.00 price target on shares of Viewray in a research report on Monday, November 13th. Cantor Fitzgerald set a $13.00 price target on Viewray and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub raised Viewray from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine downgraded Viewray from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Viewray has an average rating of “Buy” and an average target price of $11.58.
Viewray (NASDAQ:VRAY) opened at $7.88 on Thursday. The firm has a market capitalization of $551.83, a P/E ratio of -7.23 and a beta of 14.36. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67. Viewray has a 12-month low of $4.40 and a 12-month high of $10.64.
Institutional investors have recently bought and sold shares of the company. Pura Vida Investments LLC grew its position in shares of Viewray by 132.9% in the third quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after purchasing an additional 346,370 shares during the last quarter. Fosun International Ltd acquired a new position in shares of Viewray in the third quarter valued at approximately $640,000. Vanguard Group Inc. grew its position in shares of Viewray by 67.0% in the second quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock valued at $6,644,000 after purchasing an additional 411,866 shares during the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Viewray in the second quarter valued at approximately $323,000. Finally, Granite Investment Partners LLC acquired a new position in shares of Viewray in the third quarter valued at approximately $492,000. 50.52% of the stock is currently owned by institutional investors.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.